NMR Group Project: Preparation and Properties of Novel M

NMR 课题组项目:Novel M 的制备及性能

基本信息

项目摘要

An established hallmark of tumorigenesis is the biosynthesis of aberrant glycan chains due to changes in the expression of glycoprocessing enzymes in tumor tissue. These aberrations become more marked as the tumor acquires a more aggressive phenotype. Tumor cell-surface carbohydrates play important roles in the motility and metastasis of many different cancer cells. In addition, many of these aberrant glycans are tumor-associated carbohydrate antigens (TACA) and have been used in the development of tumor vaccines. Since most of the cellular interactions with TACA's are not well understood, there is an urgent need to better characterize the specific molecular interactions that occur during these events. One feature of carbohydrate binding to macromolecules that is well understood is the concept of multivalency: Monomer carbohydrates bind to proteins very weakly while "clustering" of a monomer raises this affinity as much as a million-fold. We have prepared the important Thomsen-Friedenreich (Tf) antigen (Gal(beta)1-3GalNAc(alpha)-O-Ser/Thr) on very specific templates to take advantage of this so-called "cluster glycoside effect". As mentioned in the last report, we have prepared gold self-assembled nanospheres and quantum dots containing sugar derivative and reported preliminary details on their function. The in vivo experiments with our gold nanospheres in mice were repeated twice with varying results. However, these were caused by the use of a tumor cells that had had a different genetic makeup than the original and an error in the amount of tumor used. We have done further in vitro characterization of the gold particles and found them to act differently than monovalent sugar molecules. A large in vivo study has yielded conflicting but highly provocative results with varying concentrations of particles being tested against control (linker-only) nanoparticles. We seem to be able to inhibit primary tumor growth in vivo, but we possibly promote metastasis with particles of larger hydrodynamic volume. In the last report we reported synthesis of mucin glycopeptides and developed new linker technology to attach these to gold particles. Synthesis of gold particles with 2 glycopeptides has been achieved and characterization is in full swing. Preliminary in vitro testing showed funcytional sugar untis on the gold particles. In our quantum dots (qdots) work, we showed that contain Tf antigen-containing Qdots are functional but we needed to develop technology that removed the negative charge on our original design. WE now feel that our qdots may be more stable than commercial qdots since ours do not precipitate on size exclusion membranes during concentration experiments. We are scaling up our process and will supply several collaborators with material for labeling studies. We are very excited about the prospects for both families of particles that are being developed.
肿瘤发生的一个既定标志是由于肿瘤组织中糖加工酶表达的变化而生物合成异常聚糖链。当肿瘤获得更具侵袭性的表型时,这些畸变变得更加明显。肿瘤细胞表面碳水化合物在许多不同癌细胞的运动和转移中发挥重要作用。此外,许多异常聚糖是肿瘤相关糖抗原(TACA),已用于肿瘤疫苗的开发。由于大多数细胞与 TACA 的相互作用尚不清楚,因此迫切需要更好地表征这些事件期间发生的特定分子相互作用。碳水化合物与大分子结合的一个众所周知的特征是多价概念:单体碳水化合物与蛋白质的结合非常弱,而单体的“聚集”则将这种亲和力提高了数百万倍。我们在非常特异的模板上制备了重要的 Thomsen-Friedenreich (Tf) 抗原(Gal(beta)1-3GalNAc(alpha)-O-Ser/Thr),以利用这种所谓的“簇糖苷效应”。正如上一篇报告中提到的,我们制备了金自组装纳米球和含有糖衍生物的量子点,并报告了其功能的初步细节。我们的金纳米球在小鼠体内的体内实验重复了两次,结果各不相同。然而,这些都是由于使用的肿瘤细胞的基因组成与原始细胞不同以及肿瘤细胞用量的错误造成的。我们对金颗粒进行了进一步的体外表征,发现它们的作用与单价糖分子不同。一项大型体内研究产生了相互矛盾但极具争议性的结果,其中针对对照(仅连接体)纳米粒子测试了不同浓度的粒子。我们似乎能够抑制体内原发性肿瘤的生长,但我们可能会用较大流体动力学体积的颗粒促进转移。在上一份报告中,我们报道了粘蛋白糖肽的合成,并开发了新的连接技术将其附着到金颗粒上。已实现金颗粒与2种糖肽的合成,表征工作正在紧锣密鼓地进行中。初步体外测试显示金颗粒上存在功能性糖。在我们的量子点 (qdot) 工作中,我们证明含有 Tf 抗原的 Qdot 是有功能的,但我们需要开发技术来消除我们原始设计上的负电荷。我们现在认为我们的量子点可能比商业量子点更稳定,因为我们的量子点在浓度实验期间不会沉淀在尺寸排阻膜上。我们正在扩大我们的流程,并将向一些合作者提供用于标签研究的材料。我们对正在开发的这两个粒子家族的前景感到非常兴奋。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joseph John Barchi其他文献

Joseph John Barchi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joseph John Barchi', 18)}}的其他基金

NMR Group Project: Biophysical Studies of Oligonucleotid
NMR 小组项目:寡核苷酸的生物物理研究
  • 批准号:
    7053872
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Carbohydrate Antigen-bearing Nanoparticles for Anti-adhesives and Tumor Vaccines
用于抗粘连剂和肿瘤疫苗的携带碳水化合物抗原的纳米颗粒
  • 批准号:
    8552700
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Carbohydrate Antigen-bearing Nanoparticles for Antitumor Therapy
用于抗肿瘤治疗的碳水化合物抗原纳米颗粒
  • 批准号:
    9343623
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Carbohydrate Antigen-bearing Nanoparticles for Antitumor Therapy
用于抗肿瘤治疗的碳水化合物抗原纳米颗粒
  • 批准号:
    10702356
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Carbohydrate Antigen-bearing Nanoparticles for Anti-adhesives and Tumor Vaccines
用于抗粘连剂和肿瘤疫苗的携带碳水化合物抗原的纳米颗粒
  • 批准号:
    8349011
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Carbohydrate Antigen-bearing Nanoparticles for Antitumor Therapy
用于抗肿瘤治疗的碳水化合物抗原纳米颗粒
  • 批准号:
    10262091
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Synthesis /Biology /Conformation Study of Tumor Antigens
肿瘤抗原的合成/生物学/构象研究
  • 批准号:
    6753251
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
NMR Group Project: Structural Analysis of Conformational
NMR 小组项目:构象的结构分析
  • 批准号:
    6763822
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
A Glycopeptide from Interstitial Cystitis Patients as a Novel Anticancer Lead
来自间质性膀胱炎患者的糖肽作为新型抗癌先导化合物
  • 批准号:
    10486798
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
NMR Group Project: Biophysical Studies of Oligonucleotid
NMR 小组项目:寡核苷酸的生物物理研究
  • 批准号:
    7291782
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:

相似国自然基金

信息交流对异质性团体感知觉决策的影响研究:基于认知计算的动态优势表征
  • 批准号:
    32300910
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
团体创新中的观念生成路径及其神经基础研究
  • 批准号:
    32300900
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
基于分子互作研究多酚结构差异对面团体系面筋蛋白网络形成的调控机制
  • 批准号:
    32301998
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
面向小团体的多模态连续情感识别研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    53 万元
  • 项目类别:
    面上项目
位置社交网络中天际线团体搜索技术研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    54 万元
  • 项目类别:
    面上项目

相似海外基金

Innovative Tools for Chemical Synthesis: Metal-Hydride Catalysis, Medicinal Motifs, and Molecular Probes
化学合成的创新工具:金属氢化物催化、药用基序和分子探针
  • 批准号:
    10624041
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
North American Mitochondrial Disease Consortium (NAMDC)
北美线粒体疾病联盟 (NAMDC)
  • 批准号:
    8339450
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
North American Mitochondrial Disease Consortium (NAMDC)
北美线粒体疾病联盟 (NAMDC)
  • 批准号:
    8537981
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Project 1/Computational Core
项目1/计算核心
  • 批准号:
    7449170
  • 财政年份:
    2008
  • 资助金额:
    --
  • 项目类别:
Advanced Multimodal Neuroimaging Training Grant
高级多模式神经影像培训补助金
  • 批准号:
    7294257
  • 财政年份:
    2006
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了